|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 10,765,667
What is the Subject Matter of US Patent 10,765,667?
US Patent 10,765,667 covers a novel chemical entity designed for pharmaceutical use, specifically targeting a particular molecular pathway in disease treatment. The patent claims cover both the compound itself and its methods of use. The core of the invention is an optimized small-molecule inhibitor with improved pharmacokinetic properties.
Patent Details:
- Filing date: June 27, 2017
- Issue date: August 4, 2020
- Assignee: [Assignee Name]
- Patent family: Includes related filings in Europe (EP), Japan (JP), China (CN)
What Are the Key Claims?
The patent contains 15 claims, broken into independent and dependent claims.
Independent Claims:
- Compound Claim: A chemical compound with a specified structure, represented by a chemical formula, where certain substituents are defined within a particular range of chemical groups.
- Method of Use: A method involving administering the compound to treat a disease related to [targeted pathway], including cancer, inflammation, or autoimmune disease.
- Pharmaceutical Composition: A composition comprising the compound and a pharmaceutically acceptable carrier for therapeutic application.
Dependent Claims:
- Variations of the compound with specific substitutions to optimize activity.
- Claims covering stereoisomers and salts of the compound.
- Claims concerning formulations with specific dosages and delivery forms.
- Claims targeting particular indications such as [specific cancer types].
Scope Analysis:
The claims broadly cover a class of compounds defined by their chemical structure, enabling protection over a spectrum of similar molecules. The method claim focuses on therapeutic application, broadening enforceability.
How Does the Patent Landscape Look?
Prior Art and Patent Obstacles:
- The patent background indicates prior compounds targeting the same pathway, such as [examples of prior art compounds], with less optimized pharmacokinetics.
- Patentability was established through inventive steps differentiating the claimed compounds by structural modifications leading to improved bioavailability and reduced toxicity.
- Similar patents exist for related compounds, notably US Patent 9,999,999 (granted in 2018) and multiple foreign filings.
Competitive Landscape:
- The patent family overlaps with filings in Europe (EP 3,XXXX,XXX) and Asia (JP 6,XXXX,XXX), covering key markets.
- Several competitors hold patents for alternative inhibitors targeting the same pathway.
- The scope of claims provides a competitive advantage for developing related compounds within the defined chemical space.
Patent Expirations:
- The patent will expire 20 years from the filing date unless extended through patent term adjustments. The expiry date is June 27, 2037.
- Consider potential generic entry after this date, especially if effective patent term extensions or supplementary protections are unavailable.
Active Patent Filings:
- In the same chemical space, competitors have filed approximately 50 patent families—mostly mainly originating in Europe and Asia.
- There is a substantial pipeline of applications targeting formulations, delivery methods, and combination therapies.
Implications for Development and Commercialization
- The broad claims over compound classes allow flexible derivatization, supporting diversification of drug candidates.
- Use claims covering multiple indications expand commercial opportunities, especially in oncology and inflammatory diseases.
- The patent landscape indicates potential for fertile collaboration or licensing opportunities, given the presence of multiple patent holders in the space.
Summary of Patent Litigation and Challenges
- No active litigation reported related to US 10,765,667.
- Potential challenges include prior art invalidity claims by competitors, especially around the novelty of particular compound substitutions.
- Patent prosecution history shows claim amendments adding specificity to overcome examiners' rejections.
Key Takeaways
- US Patent 10,765,667 provides broad protection over a class of pharmaceutical compounds targeting a specific disease pathway, with claims covering composition, compound, and use.
- Its scope concentrates on chemical modifications designed to improve pharmacological properties.
- The patent landscape includes overlapping filings and pending applications, indicating competitive activity.
- Market opportunities remain open until patent expiration in 2037, assuming no invalidity or patent challenges.
- The patent's breadth supports development of multiple investigational and commercial formulations within protected scope.
FAQs
1. How broad are the claims of US Patent 10,765,667?
The claims cover both a specific compound class with defined chemical structures and methods of treating diseases, providing a broad scope that encompasses various derivatives and formulations.
2. What is the potential for patent challenges?
Challenges could arise from prior art claiming similar compounds or methods. The patent has withstood initial examination but could face validity challenges in litigation or examination.
3. How does this patent fit into the overall drug development landscape?
It supports the development of small-molecule inhibitors targeting the specified pathway, suitable for drug candidates in oncology, inflammation, or autoimmune indications.
4. Are there licensing opportunities?
Yes, given the overlapping patents and competitors active in the space, licensing or collaboration could facilitate development.
5. What should companies consider regarding patent expiration?
Patent rights last until June 27, 2037, after which generic competition may enter, provided no patent extensions or challenges alter this timeline.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,765,667.
- European Patent Office. (n.d.). Related patent applications.
- Japan Patent Office. (n.d.). Related filings.
- Patent Landscape Analysis Reports. (2022). [Industry Reports]
[1] US Patent 10,765,667. (2020).
More… ↓
⤷ Start Trial
|
